Immuneering’s (IMRX) “Buy” Rating Reiterated at Needham & Company LLC

Immuneering (NASDAQ:IMRX)‘s stock had its “buy” rating reiterated by research analysts at Needham & Company LLC in a research report issued on Monday,Benzinga reports. They presently have a $11.00 price target on the stock. Needham & Company LLC’s price objective points to a potential upside of 106.38% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. Chardan Capital reaffirmed a “buy” rating and set a $20.00 price target on shares of Immuneering in a research note on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Immuneering from a “sell” rating to a “hold” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $16.50.

Immuneering Stock Up 7.0%

Shares of NASDAQ IMRX opened at $5.33 on Monday. The company’s fifty day moving average is $5.22 and its 200-day moving average is $6.12. The stock has a market cap of $344.16 million, a price-to-earnings ratio of -3.86 and a beta of 0.46. Immuneering has a twelve month low of $1.10 and a twelve month high of $10.08.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Friday, March 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.13. On average, research analysts anticipate that Immuneering will post -1.86 EPS for the current fiscal year.

Insider Transactions at Immuneering

In related news, Director Peter Feinberg bought 20,000 shares of Immuneering stock in a transaction that occurred on Monday, January 12th. The stock was acquired at an average price of $4.35 per share, with a total value of $87,000.00. Following the acquisition, the director owned 135,441 shares of the company’s stock, valued at approximately $589,168.35. This represents a 17.32% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Thomas J. Schall purchased 21,645 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was bought at an average price of $4.67 per share, for a total transaction of $101,082.15. Following the purchase, the director owned 74,530 shares in the company, valued at $348,055.10. The trade was a 40.93% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 51,819 shares of company stock valued at $234,472. 22.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immuneering

Large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new stake in Immuneering in the 4th quarter valued at $33,000. China Universal Asset Management Co. Ltd. bought a new position in Immuneering during the 3rd quarter worth $35,000. Future Financial Wealth Managment LLC bought a new position in Immuneering during the 3rd quarter worth $35,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Immuneering during the third quarter worth $70,000. Finally, SummitTX Capital L.P. acquired a new stake in shares of Immuneering during the fourth quarter worth $69,000. Institutional investors own 67.65% of the company’s stock.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.